Kaiser R
Geburtshilfe Frauenheilkd. 1993 Jul;53(7):503-13. doi: 10.1055/s-2007-1022924.
The first experimental and clinical investigations with gestagen-oestrogen combinations were undertaken in the late 'forties and the early' fifties of this century. In the course of further research and development, the dosage and mixture ratio of this hormonal principle were adjusted, according to the physiological status of the corpus luteum phase and its imitation by means of administration of hormonal doses. Considering the relatively large individual variations, an average daily production of 0.05 mg oestradiol/oestrone and 25 mg progesterone can be assumed, the mixture ratio being 1:50. Further indicators for the dosage were obtained by studying the biological valency of the semi-synthetic substances on the basis of the following parameters: transformation dose, menstruation delay test, anti-oestrogenic effectiveness and ovulation inhibition dose. Finally, dosage was also determined by the relevant indications; in this respect, depending on the intended use, preparations with the emphasis either on the oestrogen component or the gestagen component were deliberately produced. Up to the end of the 'fifties', parenteral gestagen-oestrogen combinations were the only preparations available for gynaecological hormonal therapy. Oral medication was predominant from 1957 onwards. The high ranking achieved by the combination preparations was due to their properties with respect to regulating menstrual haemorrhage and inhibiting proliferation and ovulation, as well as to their antiandrogenic properties. As far as methods of application were concerned, cyclical administration was most frequently employed (including phase variants), therapeutic amenorrhoea being second, whereas high-dosage application in the sense of hormonal pseudopregnancy was less often used. The gestagen-oestrogen combinations have become the most important hormonal principle in gynaecology as therapeutic agents and hormonal contraceptives.
对孕激素 - 雌激素组合进行的首次实验和临床研究是在本世纪四十年代末和五十年代初开展的。在进一步的研发过程中,根据黄体期的生理状态以及通过给予激素剂量来模拟该状态,对这种激素制剂的剂量和混合比例进行了调整。考虑到个体差异相对较大,可以假定雌二醇/雌酮的日均产量为0.05毫克,孕酮为25毫克,混合比例为1:50。通过基于以下参数研究半合成物质的生物效价,获得了关于剂量的进一步指标:转化剂量、月经推迟试验、抗雌激素效力和排卵抑制剂量。最后,剂量也由相关适应症确定;在这方面,根据预期用途,特意生产了侧重于雌激素成分或孕激素成分的制剂。直到五十年代末,肠胃外孕激素 - 雌激素组合一直是妇科激素治疗唯一可用的制剂。从1957年起,口服药物占主导地位。组合制剂获得高度评价是由于它们在调节月经出血、抑制增殖和排卵方面的特性,以及它们的抗雄激素特性。就应用方法而言,最常采用周期性给药(包括不同阶段的变体),其次是治疗性闭经,而激素假孕意义上的高剂量应用较少使用。孕激素 - 雌激素组合已成为妇科中作为治疗剂和激素避孕药最重要的激素制剂。